cbdMD, Inc. (NYSEAMERICAN:YCBD – Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 1,041,977 shares, an increase of 43.7% from the January 29th total of 725,021 shares. Approximately 10.6% of the shares of the company are sold short. Based on an average daily volume of 687,845 shares, the short-interest ratio is presently 1.5 days. Based on an average daily volume of 687,845 shares, the short-interest ratio is presently 1.5 days. Approximately 10.6% of the shares of the company are sold short.
Insiders Place Their Bets
In other cbdMD news, major shareholder Clark R. Crosnoe sold 550,701 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $2.32, for a total transaction of $1,277,626.32. Following the transaction, the insider directly owned 17,875 shares of the company’s stock, valued at approximately $41,470. This trade represents a 96.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On cbdMD
A hedge fund recently bought a new stake in cbdMD stock. Jane Street Group LLC purchased a new position in cbdMD, Inc. (NYSEAMERICAN:YCBD – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned 0.49% of cbdMD at the end of the most recent reporting period. Institutional investors own 7.18% of the company’s stock.
cbdMD Price Performance
About cbdMD
cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.
The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.
See Also
- Five stocks we like better than cbdMD
- The gold chart Wall Street is terrified of…
- This makes me furious
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.
